Finasteride Treatment of Severe Nodulocystic Acne

PHASE2CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

June 6, 2017

Study Completion Date

June 6, 2017

Conditions
NODULOCYSTIC ACNE
Interventions
DRUG

Finasteride 23.5 mg tablets

DRUG

Finasteride 33.5 mg tablets

DRUG

Placebo tablets

Trial Locations (25)

10012

Greenwich Village Dermatology, New York

19103

Paddington Testing Co., Inc., Philadelphia

29169

Invocare Clinical Research Center, West Columbia

30060

Marietta Dermatology Clinical Research, Inc., Marietta

30263

MedaPhase, Inc., Newnan

32073

Park Avenue Dermatology, Orange Park

32771

International Clinical Research, Sanford

33172

Lenus Research & Medical Group, Sweetwater

33174

Advanced Medcial Research Institiute, Miami Lakes

33511

MOORE Clinical Research, Inc., Brandon

44106

UHCMC Skin Study Center, Cleveland

46168

The Indiana Clinical Trials Center, PC, Plainfield

46256

Dawes Fretzin Clinical Research Group. LLC, Indianapolis

48059

Hamzavi Dermatology, Fort Gratiot

60089

Glazer Dermatology, Buffalo Grove

60181

Summit Dermatology, Oakbrook Terrace

60611

Northwestern University, Chicago

64506

MediSearch Clinical Trials, Saint Joseph

71913

Burke Pharmaceutical Research, Hot Springs

80220

Horizons Clinical Research Center, LLC., Denver

83704

Northwest Clinical Trials, Boise

85018

Omni Dermatology, Inc., Phoenix

90036

Axis Clinical Trials, Los Angeles

90210

Dr. Ronald Moy, Beverly Hills

92780

Orange County Research Center, Tustin

All Listed Sponsors
lead

Elorac, Inc.

INDUSTRY

NCT02502669 - Finasteride Treatment of Severe Nodulocystic Acne | Biotech Hunter | Biotech Hunter